FAM83A Promotes Lung Cancer Progression by Regulating the Wnt and Hippo Signaling Pathways and Indicates Poor Prognosis
Frontiers in Oncology, ISSN: 2234-943X, Vol: 10, Page: 180
2020
- 46Citations
- 17Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations46
- Citation Indexes46
- 46
- Captures17
- Readers17
- 17
Article Description
FAM83A (family with sequence similarity 83, member A) has been found to be highly expressed in cancers. The purpose of this study was to clarify the role and mechanism of FAM83A in lung cancers. The expression of FAM83A in lung cancer cells was enhanced by gene transfection or knocked down by small interfering RNA interference. The key proteins of the Wnt signaling pathway, the Hippo signaling pathway, and epithelial–mesenchymal transition (EMT) were examined using Western blot. The proliferation and invasion of lung cancer cells were examined using cell proliferation, colony formation, and invasion assays. The expression of FAM83A in lung cancer tissues was significantly increased and was correlated with advanced tumor–node–metastasis (TNM) stage and poor prognosis. Overexpression of FAM83A enhanced the proliferation, colony formation, and invasion of lung cancer cells. Meanwhile, FAM83A overexpression increased the expression of active β-catenin and Wnt target genes and the activity of EMT. Furthermore, in FAM83A-overexpressed cells, the activity of Hippo pathway was downregulated, whereas the expression of yes-associated protein (YAP) and its downstream targets cyclin E and CTGF were upregulated. The inhibitor of the Wnt signaling pathway, XAV-939, reversed the promoting effect of FAM83A on YAP, cyclin E, and CTGF. On knocking down the expression of FAM83A, we obtained the opposite results. However, the inhibitor of GSK3β, CHIR-99021, restored the expression of YAP, cyclin E, and CTGF after FAM83A was knocked down. FAM83A is highly expressed in lung cancers and correlated with advanced TNM stage and poor prognosis. FAM83A promotes the proliferation and invasion of lung cancer cells by regulating the Wnt and Hippo signaling pathways and EMT process.
Bibliographic Details
10.3389/fonc.2020.00180; 10.3389/fonc.2020.00180.s002; 10.3389/fonc.2020.00180.s001; 10.3389/fonc.2020.00180.s004; 10.3389/fonc.2020.00180.s003
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85082666771&origin=inward; http://dx.doi.org/10.3389/fonc.2020.00180; http://www.ncbi.nlm.nih.gov/pubmed/32195172; https://www.frontiersin.org/articles/10.3389/fonc.2020.00180/supplementary-material/10.3389/fonc.2020.00180.s002; http://dx.doi.org/10.3389/fonc.2020.00180.s002; https://www.frontiersin.org/articles/10.3389/fonc.2020.00180/supplementary-material/10.3389/fonc.2020.00180.s001; http://dx.doi.org/10.3389/fonc.2020.00180.s001; https://www.frontiersin.org/article/10.3389/fonc.2020.00180/full; https://www.frontiersin.org/articles/10.3389/fonc.2020.00180/supplementary-material/10.3389/fonc.2020.00180.s004; http://dx.doi.org/10.3389/fonc.2020.00180.s004; https://www.frontiersin.org/articles/10.3389/fonc.2020.00180/supplementary-material/10.3389/fonc.2020.00180.s003; http://dx.doi.org/10.3389/fonc.2020.00180.s003; https://dx.doi.org/10.3389/fonc.2020.00180.s002; https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00180/full; https://dx.doi.org/10.3389/fonc.2020.00180.s004; https://dx.doi.org/10.3389/fonc.2020.00180; https://dx.doi.org/10.3389/fonc.2020.00180.s003; https://dx.doi.org/10.3389/fonc.2020.00180.s001
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know